Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults
Shots:
- The NDA was submitted based on the P-III (GLORY-1) trial evaluating the safety & efficacy of Mazdutide (4 or 6mg) vs PBO in Chinese overweight or obese adults
- The results depicted superior effects of Mazdutide vs PBOs in body weight change from baseline to wk32 & proportion of participants with a weight loss of ≥5% at wk32 along with the proportion with a weight loss of ≥10% or ≥15%, changes in waist circumference, systolic BP, TG, LDL-C, total cholesterol, serum uric acid & ALT. The results are expected to be presented at upcoming medical conferences in 2024
- Innovent signed an exclusive license agreement with Eli Lilly for the development & potential commercialization of Mazdutide (OXM3), a GLP-1R & GCGR dual agonist
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the Result Of Mazdutide (IBI362) in the P-II Study on Chinese Patients with Type-2 Diabetes (T2D)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
